Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma-Reference-Cited by-同舟云学术

Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma

Published:2022-07 Issue:7 Volume:22 Page:e498-e506
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Kaddu-Mulindwa Dominic^ORCID,Gödel Philipp,Kutsch Nadine^ORCID,Heger Jan-Michel^ORCID,Scheid Christof,Borchmann Peter,Holtick Udo,Held Gerhard,Thurner Lorenz,Bewarder Moritz^ORCID,Rixecker Torben,Bittenbring Joerg-Thomas

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases;Salar;Eur J Haematol,2009

2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues;Swerdlow,2017

3. Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

5. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials;eJHaem;2023-10-09

2. Melphalan;Reactions Weekly;2023-07-08

3. Does ferritin level affect the outcomes of autologous stem cell transplantation equally in all diseases?;Transfusion and Apheresis Science;2023-06